Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvio Garattini

Showing results (1-10 of 165) with videos related to

Pageof 17
Sort By:
European Journal of Clinical Pharmacology|March 12, 2005
Designing the most favourable study designSilvio Garattini
European Journal of Clinical Pharmacology|March 9, 2021
Quality, efficacy, safety-it is not enough!Silvio Garattini
Journal of Cardiovascular Medicine (Hagerstown, Md.)|October 19, 2007
Long-chain n-3 fatty acids in lipid rafts: implications for anti-inflammatory effectsSilvio Garattini
European Journal of Clinical Pharmacology|August 16, 2011
Time to revisit the orphan drug lawSilvio Garattini
Lancet (London, England)|October 15, 2013
Reconsidering the Declaration of HelsinkiSilvio Garattini
Recenti Progressi in Medicina|April 12, 2017
[Homeopathic drug products and outpatient clinics: are they deceiving the public?]Silvio Garattini
Pharmacoeconomics|August 5, 2010
Evaluation of benefit-riskSilvio Garattini
Recenti Progressi in Medicina|June 16, 2015
[Great discoveries: from the painstaking efforts of researchers to the contribution of accidental findings and the dissemination of study results]Silvio Garattini
The Journal of Ambulatory Care Management|April 9, 2004
The cultural shift in Italy's pharmaceutical policy in 1994: a case historySilvio Garattini
Pharmacoeconomics|April 20, 2005
EMEA: for patients or for industry?Silvio Garattini
Pageof 17

Showing results (1-10 of 165) with videos related to

Sort By:
Pageof 17
European Journal of Clinical Pharmacology|March 12, 2005
Designing the most favourable study designSilvio Garattini
European Journal of Clinical Pharmacology|March 9, 2021
Quality, efficacy, safety-it is not enough!Silvio Garattini
Journal of Cardiovascular Medicine (Hagerstown, Md.)|October 19, 2007
Long-chain n-3 fatty acids in lipid rafts: implications for anti-inflammatory effectsSilvio Garattini
European Journal of Clinical Pharmacology|August 16, 2011
Time to revisit the orphan drug lawSilvio Garattini
Lancet (London, England)|October 15, 2013
Reconsidering the Declaration of HelsinkiSilvio Garattini
Recenti Progressi in Medicina|April 12, 2017
[Homeopathic drug products and outpatient clinics: are they deceiving the public?]Silvio Garattini
Pharmacoeconomics|August 5, 2010
Evaluation of benefit-riskSilvio Garattini
Recenti Progressi in Medicina|June 16, 2015
[Great discoveries: from the painstaking efforts of researchers to the contribution of accidental findings and the dissemination of study results]Silvio Garattini
The Journal of Ambulatory Care Management|April 9, 2004
The cultural shift in Italy's pharmaceutical policy in 1994: a case historySilvio Garattini
Pharmacoeconomics|April 20, 2005
EMEA: for patients or for industry?Silvio Garattini
Pageof 17